Compare Abbott Laboratories (ABT) vs Otis Worldwide Corp (OTIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Otis Worldwide Corp — how do they compare? Abbott Laboratories trades at $95.37 (market cap $166.94B), while Otis Worldwide Corp trades at $72.34 (market cap $28.18B). The key difference: Abbott Laboratories is far larger — about 5.9× Otis Worldwide Corp's market cap, and Abbott Laboratories pays the higher dividend (2.63%). Which is the better fit depends on your goals.
| ABT | OTIS | |
|---|---|---|
Market Cap | $166.94B | $28.18B |
Sector | Health | Industrials |
52-Week High | $136.62 | $101.07 |
52-Week Low | $82.57 | $69.34 |
Enterprise Value | $193.69B | $35.56B |
Dividend Yield | 2.63% | 2.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
OTIS trades at $73.43, up 0.4% today, with a bullish technical signal and strong support at $72. The company reported $14.43B in 2025 revenue, a 10.11% net income margin, and a P/E of 19.55. Recent news highlights elevator modernization projects and a 5% dividend increase to $0.44 per share. Earnings have been mixed, with a Q1 2026 miss but service segment growth.
The stock offers a 28% upside to the $94 consensus price target, supported by buybacks and dividend growth, but faces risks from high debt and margin pressure. Analyst sentiment is mixed with 38% buy ratings. Execution on service growth and cost management is critical for re-rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Otis Worldwide Corp
Otis is the largest global elevator and escalator supplier by revenue with around one quarter of share excluding Japan. In 1854 Otis' founder and namesake, Elisha Graves Otis, invented a safety mechanism that prevented elevators from falling if the hoisting cable failed.The company's product and service lifecycle begins with installations of elevator units in new buildings, later selling maintenance services on the units, and eventually replacement of the units after the average 15-20 year useful life of an elevator. As the largest global OEM, over decades Otis has built a base of 2 million elevators under service. Its business model is much the same as that of its competitors Kone, Schindler, and Thyssenkrupp.
Read more on OTIS →
